6CM
TBPH icon

683 Capital Management’s Theravance Biopharma TBPH Stock Holding History

683 Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250,000
Closed -$4.06M – 237
2026
Q1 		$4.06M Buy
+250,000
New +$4.42M 0.21% 81

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

683 Capital Management's TBPH Position: Q2 2026 in Review

683 Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 250,000 shares — an estimated $4.06M sold.

683 Capital Management first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $4.06M in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • 683 Capital Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 250,000 Theravance Biopharma shares in Q2 2026, an estimated $4.06M.
  • 683 Capital Management first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
  • 683 Capital Management's Theravance Biopharma position peaked at $4.06M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.